In 10 days, 9 biomedical companies issued the total amount of mergers and acquisitions involved in the merger and acquisition announcement of over 2.7 billion yuan

Our reporter Xu Jie

Profile reporter Jin Satellite

On the evening of August 9, East China Pharmaceutical disclosed that the company's wholly -owned subsidiary China and the United States planned to acquire 60%of Huaren Technology's equity in the form of capital increase and transfer, and became its controlling shareholder, with a total of not more than 396 million yuan Essence On the same day, Dorui Pharmaceutical announced that the company intends to acquire 40%of the 40%equity of Luzhou Tianji held by Hubei Tianji.

Recently, the A -share biomedical field has been active. Tongllow iFind data shows that since August, a total of 9 A -share pharmaceutical biological institutions have launched mergers and acquisitions within 10 days, involving a total amount of over 2.7 billion yuan. Overall, the reason for the acquisition includes supplementary companies' technology and customer base accumulation in the innovation sector, improve the industrial layout, and enhance the company's profitability.

The industry investment director of a medical investment institution told the Securities Daily reporter: "Compared with other industries, there are several characteristics of the pharmaceutical industry. One is relatively strong in supervision of the industry, the second is that the entry threshold is high, and the third is effective. Production resources are relatively concentrated. In addition, drug research and development, especially the research and development of innovative drugs, has the characteristics of long R & D cycle, large R & D expenses, high R & D talent dense, and relatively high product failure rate. Based on the above characteristics The product line, the cost of self -built is large, mergers and acquisitions are a more effective way to obtain resources. At the same time, this is a trend that can improve the efficiency of the industry, save the industry's repeated research and development costs, and meet the industry development rules. "

The maximum merger acquisition amount exceeds 1 billion yuan

Regarding the impact of the above acquisition on the company, East China Pharmaceutical said that the acquisition of Huaren Technology will quickly supplement the technology accumulation and customer resources of the company's industrial microbial nucleosides in the above fields. Effective collaboration with industrial layout. Dorui Pharmaceutical said that the company's investment in Bozhou Tianji will help accelerate and improve the company's Chinese medicine industry layout, and help further enhance the company's profitability.

Among the 10 mergers and acquisitions, the maximum merger and acquisition involved over 1 billion yuan. On August 7, a well -known company announced that it intends to purchase part of the equity of a Guangzhou pharmaceutical company at a cash of about 1.03 billion yuan. After the transaction is completed, the company will hold more than 90%of the shares of the acquisition.

China Resources Pharmaceuticals carried out two acquisitions that involved a total amount of more than 800 million yuan. China Resources Pharmaceutical announced on August 4 that its China Resources Shuanghe Pharmaceutical Co., Ltd. (hereinafter referred to as "China Resources Shuanghe") acquired 50.11%of Shenzhou Biotechnology for 501 million yuan, and increased its holdings of Tiandong Pharmaceutical 31.25%for 307 million yuan. The equity of the equity holds a total of 70%of the shares of Tiandong Pharmaceutical after increasing its holdings.

In this regard, China Resources Pharmaceutical said that the acquisition of Shenzhou Biological Equity is expected to help enhance future profitability, realize business layout, quickly enter the field of biological fermentation, improve product acquisition capabilities in the field of biological fermentation, and enrich product pipelines. The purpose of increasing holdings of Tiandong Pharmaceuticals is to accelerate the integration of resources and promote the rapid development of Tiandong Pharmaceutical, thereby improving profitability and comprehensive competitiveness.

In addition, many companies have accelerated the pace of mergers and acquisitions. Shenzhen Micro Capital Biotechnology announced on August 6 that the acquisition of some equity of Chengdu Micro Capital Pharmaceutical Co., Ltd., the acquisition amount was 260 million yuan; Guangdong Chenghui Medical announced on August 3 that the capital increase was 15 million yuan to acquire Guangdong Cinho medical treatment Part of the equity of investment Co., Ltd.; Qidi Pharmaceutical announced on August 3 that it purchased 100%equity of Guangdong Xiantong Pharmaceutical Co., Ltd. for 220 million yuan.

What is the frequent mergers and acquisitions?

The same flower Shunian data shows that in the M & A statistics in the past three years, the biomedical industry is second only to the machinery and equipment industry. The proportion of equipment is 8.46%.

In response to the active phenomenon of mergers and acquisitions of A -share pharmaceutical biological companies, Chen Bin, head of drug registration and clinical development of Chengdu Telin Enterprise Management Co., Ltd., told the Securities Daily reporter that M & A in this field has become an industry trend. On the one hand, the biomedical industry itself is a business model of re -developing and developing and developing technology; on the other hand, industry development and technological progress are faster. In this context, listed companies want to seize the opportunity to expand pipelines and develop cutting -edge technologies. It takes a long time and high cost of self -construction. The acquisition of related targets is a more efficient choice.

A biomedicine VC, who is unknown to name, told the Securities Daily reporter: "In recent years, the phenomenon of mergers and acquisitions in the field of biomedicine is indeed more common. Enterprises can avoid repeated construction and disorderly expansion. The main reason for mergers and acquisitions is to make up for product lines and extensions Sales market, etc. "

"However, some listed companies have insufficient diligence in the early stage, incomplete risk recognition, and unclear bottom numbers. They do not look at market changes in the research and development targets of related technologies. ', Only pay attention to whether the financial statements in front of you are good -looking. "The above VC added that in view of this, biomedical companies should consolidate the foundation of development when conducting mergers and acquisitions activities, see problems from long -term eyes, avoid attacks around, and beware of blind expansion. Risk of business scope.

- END -